Hualan Biological Engineering Inc
SZSE:002007

Watchlist Manager
Hualan Biological Engineering Inc Logo
Hualan Biological Engineering Inc
SZSE:002007
Watchlist
Price: 15.96 CNY 0.69%
Market Cap: 29.2B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+22%
Revenue
Forecast
+14%
Operating Income
Forecast
+16%
Net Income
Forecast
+18%

Wall Street
Price Targets

Price Targets Summary
Hualan Biological Engineering Inc

Wall Street analysts forecast Hualan Biological Engineering Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Hualan Biological Engineering Inc is 19.55 CNY with a low forecast of 15.15 CNY and a high forecast of 24.47 CNY.

Lowest Forecast
Wall Street Target
15.15 CNY
5% Downside
Average Forecast
Wall Street Target
19.55 CNY
22% Upside
Highest Forecast
Wall Street Target
24.47 CNY
53% Upside
Lowest
Price Target
15.15 CNY
5% Downside
Average
Price Target
19.55 CNY
22% Upside
Highest
Price Target
24.47 CNY
53% Upside
Hualan Biological Engineering Inc Competitors:
Price Targets
GNS
Genus PLC
20% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
11% Downside
NGNE
Neurogene Inc
165% Upside
688235
Beigene Ltd
18% Upside
GNS
Genus PLC
20% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
11% Downside
NGNE
Neurogene Inc
165% Upside
688235
Beigene Ltd
18% Upside
P
214450
PharmaResearch Co Ltd
17% Downside
TRDA
Entrada Therapeutics Inc
222% Upside
9926
Akeso Inc
28% Upside
OPK
OPKO Health Inc
211% Upside

Revenue
Forecast

Revenue Estimate
Hualan Biological Engineering Inc

For the last 8 years the compound annual growth rate for Hualan Biological Engineering Inc's revenue is 11%. The projected CAGR for the next 3 years is 14%.

11%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Hualan Biological Engineering Inc

For the last 8 years the compound annual growth rate for Hualan Biological Engineering Inc's operating income is 7%. The projected CAGR for the next 3 years is 16%.

7%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Hualan Biological Engineering Inc

For the last 8 years the compound annual growth rate for Hualan Biological Engineering Inc's net income is 4%. The projected CAGR for the next 3 years is 18%.

4%
Past Growth
18%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Hualan Biological Engineering Inc's stock price target?
Price Target
19.55 CNY

According to Wall Street analysts, the average 1-year price target for Hualan Biological Engineering Inc is 19.55 CNY with a low forecast of 15.15 CNY and a high forecast of 24.47 CNY.

What is Hualan Biological Engineering Inc's Revenue forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Hualan Biological Engineering Inc's revenue is 11%. The projected CAGR for the next 3 years is 14%.

What is Hualan Biological Engineering Inc's Operating Income forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Hualan Biological Engineering Inc's operating income is 7%. The projected CAGR for the next 3 years is 16%.

What is Hualan Biological Engineering Inc's Net Income forecast?
Projected CAGR
18%

For the last 8 years the compound annual growth rate for Hualan Biological Engineering Inc's net income is 4%. The projected CAGR for the next 3 years is 18%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.